EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Cowen Starts EyePoint Pharmaceuticals, Inc. (EYPT) at Outperform
March 1, 2021 5:48 AM ESTCowen analyst Ken Cacciatore initiates coverage on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) with a Outperform rating and a price target of $25.00.
The analyst comments "EyePoint is leveraging their commercially-validated sustained release Durasert technology to develop a 6-month duration TKI (vorolanib)... More
